SI-BONE (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE reported Q3 2026 worldwide revenue of $55.7 million, up 14.5%, with U.S. procedure volume rising 19.5% and active U.S. physicians increasing 16% to 1,770. Adjusted EBITDA grew 32.4% to $3.0 million, the net loss narrowed to $3.6 million, and year-to-date operating cash flow was $4.4 million. The company reaffirmed 2026 revenue guidance of $231 million to $233 million and lowered expected operating-expense growth to 10.5% from 12%; management cited early demand for Onyx and new Medicare DRGs as potential growth drivers, while anticipating modest gross-margin pressure in 2027 from Onyx capacity depreciation.

Analysis

The key debate is whether procedure growth can convert into durable revenue and margin growth—not whether demand exists. INTRA adoption in lower-priced ASC and office settings can lift case volume while diluting revenue per case; Granite/Onyx attachment may offset that mix, but early alpha-launch utilization is not yet a reliable run rate. Hospital DRG increases are not equivalent to vendor pricing: the benefit depends on qualifying cases, hospital access, and surgeons changing practice. Treat the Onyx TAM and early-demand comparisons as management hypotheses until supported by utilization, repeat orders, and clinical outcomes.

Near term, the Q4 growth hurdle is elevated because guidance already implies acceleration; capacity deployment and seasonal strength must translate into shipped product and procedures. Over 1–3 months, watch actual Onyx availability, Granite implant count per qualifying case, and final CMS action on proposed SI-joint site-of-care payments. Over 6–18 months, adoption evidence and the CMS NTAP decision path could broaden the growth case, while added surgical-tray depreciation and investment may cap gross-margin expansion.

Contrarian angle: investors may over-credit reimbursement and headline TAM while underweighting procedure mix, capacity, and evidence-gathering timelines. Conversely, near-term margin pressure may be noncash and temporary if capacity utilization catches up. The Smith+Nephew collaboration is not yet a material underwriting input absent penetration or revenue metrics.

Key Decisions for Investors

• Keep SIBN on a catalyst watchlist rather than chase the reported growth: consider a starter long only if Q4 execution confirms acceleration and Onyx supply supports repeat use; reduce or exit if procedure growth decelerates or guidance is not met.
• Track quarterly revenue per procedure alongside procedure volume, INTRA site-of-care mix, and Granite/Onyx implants per case. If volume remains strong but per-case revenue continues to fall without improving operating leverage, the growth-to-profit thesis weakens.
• Set alerts for the final CMS site-of-care ruling and the Onyx NTAP process; do not capitalize the maximum stated hospital payment as SIBN revenue. Verify qualifying-case adoption and hospital economics before adding exposure.
• Reassess after evidence milestones: repeat utilization and prospective clinical data over the next 6–12 months matter more than alpha-launch enthusiasm. A slower rollout or gross-margin deterioration beyond management's described modest pressure would falsify the favorable operating-leverage case.